NEW YORK, June 15 /PRNewswire-FirstCall/ -- Pulmo BioTech Inc. (OTC Bulletin Board: PLMO; Frankfort Borse: PBO) has announced that it has entered into an exclusive agreement with Moody Capital Solutions, Inc. to secure up to $7.5 million in funding to enable the company to complete Phase II/III Approvals for its Pulmonary Hypertension (PH) diagnostic product candidate PulmoBind(TM).
"We are very pleased to be working with Moody Capital Solutions to raise the funding needed for our PH related Phase II/III Trials. Moody Capital Solutions, Inc. doing business as RedChip Securities, Inc. has an excellent reputation for pharma related fund raising and has substantial expertise in this area. By working with RedChip, we believe that we will be able to secure the funding to immediately start our Phase II/III work on successful completion of our Phase I Trials." - Garry McCann, CEO Pulmo BioTech Inc.
About Pulmo BioTech Inc.
Pulmo BioTech Inc. specializes in the development and marketing of medical technology and research. Our proven strengths combine extensive commercial experience and academic credentials. The principal staff members are acknowledged experts in their specialized fields, and work with a broad range of investment institutions. Our mission is to utilize scientific imagination and drive, together with managerial and financial acumen, to bring innovative and profitable products to the marketplace to the benefit of all stockholders.
About PulmoScience Inc.
PulmoScience Inc. was established in 2006, and is currently developing a non-invasive Molecular Imaging technique for the diagnosis of Pulmonary Embolism, Pulmonary Hypertension and Lung Inflammatory diseases under the trade name PulmoBind.
PulmoScience was conceived within the Montreal Heart Institute "MHI" (a world renown
|SOURCE Pulmo BioTech Inc.|
Copyright©2009 PR Newswire.
All rights reserved